Your session is about to expire
← Back to Search
Autologous Chondrocyte Implantation
CartiLife® for Osteoarthritis and Articular Cartilage Injury
Phase 2
Recruiting
Research Sponsored by Biosolution Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 (pre-operation), and up to 24 months (post-operation)
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new treatment that uses small pellets made from a patient's own cartilage cells to repair knee damage. It targets adults with knee cartilage defects caused by injury or wear and tear. The treatment aims to reduce pain and improve knee function by helping the damaged cartilage heal and regrow.
Eligible Conditions
- Articular Cartilage Injury
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 0 (pre-operation), and up to 24 months (post-operation)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 (pre-operation), and up to 24 months (post-operation)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Knee
Cartilage
Secondary study objectives
Change in IKDC (International Knee Documentation Committee) Score
Knee
Knee
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CartiLife®Experimental Treatment1 Intervention
Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
Find a Location
Who is running the clinical trial?
Biosolution Co., Ltd.Lead Sponsor
4 Previous Clinical Trials
159 Total Patients Enrolled
Jungsun Lee, Ph.DStudy DirectorBiosolution Co., Ltd.
1 Previous Clinical Trials
104 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: CartiLife®